Neutralizing prolactin receptor antibodies and their therapeutic use

US9649374B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Christiane Otto · Berlin, DE
• Siegmund Wolf · Bad Klosterlausnitz, DE
• Christoph Freiberg · Wuppertal, DE
• Axel Harrenga · Wuppertal, DE
• Simone Greven · Dormagen, DE
• Mark Trautwein · Whippany, US
• Sandra Bruder · Leverkusen, DE
• Andrea Eicker · Rheydt, DE
• Andreas Wilmen · Neunburg vorm Wald, DE

Key dates

• Filing date: Nov 18, 2010
• Grant date: May 16, 2017
• Expiry date: Nov 18, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.